Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
A. Dyer,Jean Dunne,9 Authors,S. Kennelly
2025 · DOI: 10.1002/dad2.70080
Alzheimer's & Dementia · 3 Citations
TLDR
The performance of a fully automated plasma p‐tau217 immunoassay to detect Aβ pathology in mild cognitive impairment (MCI)/mild dementia is assessed.
Abstract
Plasma phosphorylated tau (p‐tau)217 is a leading blood‐biomarker for the detection of amyloid beta (Aβ) pathology. We assessed the performance of a fully automated plasma p‐tau217 immunoassay to detect Aβ pathology in mild cognitive impairment (MCI)/mild dementia.